Hope for patients with primary hyperoxaluria type 1

June 07, 2020

Primary hyperoxaluria type 1 (PH1) is an autosomal recessive inherited disorder that begins in childhood and adolescence. Various defects in the enzyme alanine-glyoxylate aminotransferase cause an overproduction of oxalate in the liver, which is excreted in the urine (hyperoxaluria). It leads to the formation of recurrent kidney stones, renal calcification (nephrocalcinosis) and kidney injury, even kidney failure; many such patients require dialysis even before they reach adulthood. It can be managed prophylactically by drinking large amounts of fluids (2-3 litres), but this is not tolerated by smaller children, especially. Hardly any effective therapies have been available so far. In some patients, the administration of vitamin B6 (pyridoxine) can reduce oxalate excretion. Another basic therapy is to administer alkali citrate, as this improves the solubility of oxalate in urine, but no currently available treatment addresses the cause of the disease.

Lumasiran, a subcutaneously administered investigational RNAi therapeutic, could close that gap. RNA interference (RNAi) is a natural biological gene silencing mechanism. Lumasiran silences the HAO1 gene that encodes the liver enzyme GO, thereby inhibiting hepatic production of oxalate - the metabolite that directly contributes to the clinical manifestations of PH1.

At the ERA-EDTA Congress today, the results of a randomized, double-blind, placebo-controlled Phase 3 study were presented. 39 patients (age?6 years, 24hr urinary oxalate (UOx)?0.70 mmol/24hr/1.73 m2, confirmed PH1 diagnosis, eGFR?30 mL/min/1.73 m2) were randomized (2:1) and received either the investigational RNAi therapeutic or placebo once a month for 3 months followed by dosing once every 3 months. Lumasiran led to a statistically significant percent reduction in 24hr UOx excretion compared to placebo: the LS mean change from baseline after 6 months was -65.4% with lumasiran and -11.8% with placebo (LS mean difference: ?53.5%; p=1.7×10?14). Lumasiran treatment also resulted in a majority of patients achieving near-normalization (84%) or normalization (52%) of urinary oxalate (versus 0% of those treated with placebo), and reductions in mean plasma oxalate relative to placebo. The most common adverse events related to lumasiran were injection-site reactions, all of which were mild and transient; no severe or serious adverse events were reported.

"Lumasiran resulted in rapid, sustained, and statistically significant reductions in urinary and plasma oxalate levels and had an encouraging safety profile", concluded Sander Garrelfs from the Emma Children's Hospital, Amsterdam UMC, University of Amsterdam.

"We were very impressed by these results", added Maria Jose Soler Romeo, Chair of the Paper Selection Committee of the 2020 ERA-EDTA Congress. "It is now necessary to demonstrate that the drug not only reduces the overproduction of oxalate effectively, but can also prevent long-term injury to the kidneys. If that is the case, we will finally have a treatment for children and young people who are affected by this rare disease that prevents them from needing dialysis."
-end-
[1] Sander Garrelfs et al. ILLUMINATE-A, A PHASE 3 STUDY OF LUMASIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC, IN CHILDREN AND ADULTS WITH PRIMARY HYPEROXALURIA TYPE 1 (PH1). LBCT 4556, presented at the ERA-EDTA Congress 2020.

About ERA-EDTA

With more than 7,000 active members, the ERA-EDTA is one of the biggest nephrology associations worldwide leading European nephrology and one of the most important European Medical Associations. It organizes annual congresses and other educational and scientific activities. ERA-EDTA also produces guidelines, collects data, and performs epidemiological studies through its Registry. The Society supports fellowships and educational/research projects through its committees and working groups. Its publications are NDT, CKJ (Open Access journal), and the online educational journal NDT-Educational. Website http://www.era-edta.org

ERA-EDTA

Related Placebo Articles from Brightsurf:

Effect of fluvoxamine vs placebo on clinical deterioration in outpatients with symptomatic COVID-19
This randomized trial compares the effects of fluvoxamine, a selective serotonin reuptake inhibitor with immunomodulatory effects, versus placebo on a composite of dyspnea or pneumonia and oxygen desaturation among adult outpatients with polymerase chain reaction-confirmed mild COVID-19 illness.

Hydroxychloroquine no more effective than placebo in preventing COVID-19
Clinical trial with COVID-19 testing of participants shows health care workers in contact with coronavirus patients who took hydroxychloroquine each day did not reduce their rate of infection.

Compared to placebo, vitamin D has no benefit for severe asthma attacks
Contrary to earlier observational results, vitamin D supplements do not prevent severe asthma attacks in at-risk children, according to the first placebo-controlled clinical trial to test this relationship.

UMN trial shows hydroxychloroquine has no benefit over placebo in preventing COVID-19
Today, University of Minnesota Medical School researchers published the results from the first randomized clinical trial testing hydroxychloroquine for the post-exposure prevention of COVID-19.

The placebo effect and psychedelic drugs: tripping on nothing?
A new study from McGill suggests that, in the right context, some people may experience psychedelic-like effects from placebos alone.

Methotrexate reduces joint damage progression over placebo in erosive hand OA
According to new research findings presented at the 2019 ACR/ARP Annual Meeting, methotrexate did not demonstrate superior efficacy over placebo for pain relief and function evolution at three and 12 months in patients with erosive hand osteoarthritis, but did significantly reduce the progression of joint damage over placebo and seems to facilitate bone remodeling in these patients.

Botulinum toxin reduces chronic migraine attacks, compared to placebo
A growing body of evidence supports the effectiveness of botulinum toxin injections in reducing the frequency of chronic migraine headaches, concludes an updated review and analysis in the January issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons (ASPS).

Opioids vs. placebo, nonopioid alternatives for chronic noncancer pain
An estimated 50 million adults in the United States were living with chronic noncancer pain in 2016 and many of them were prescribed opioid medications, even though a clinical benefit is uncertain.

Probiotic no better than placebo for acute gastroenteritis in children
While probiotics are often used to treat acute gastroenteritis (also known as infectious diarrhea) in children, the latest evidence shows no significant differences in outcomes, compared to a placebo.

Most common shoulder operation is no more beneficial than placebo surgery
In a landmark study published this week in the BMJ, Finnish researchers show that one of the most common surgical procedures in the Western world is probably unnecessary.

Read More: Placebo News and Placebo Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.